What is William Blair’s Forecast for Biodesix Q1 Earnings?

Biodesix, Inc. (NASDAQ:BDSX) – Equities research analysts at William Blair issued their Q1 2025 earnings per share estimates for shares of Biodesix in a research report issued to clients and investors on Tuesday, March 4th. William Blair analyst A. Brackmann forecasts that the company will earn ($0.08) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Biodesix’s current full-year earnings is ($0.35) per share. William Blair also issued estimates for Biodesix’s Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.03) EPS and FY2025 earnings at ($0.22) EPS.

Biodesix (NASDAQ:BDSX) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. The company had revenue of $20.43 million during the quarter, compared to the consensus estimate of $19.92 million.

Biodesix Trading Up 20.8 %

Biodesix stock opened at $0.87 on Thursday. The firm has a 50-day moving average of $1.09 and a 200-day moving average of $1.41. Biodesix has a one year low of $0.64 and a one year high of $2.04. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.40 and a quick ratio of 3.40. The company has a market cap of $126.56 million, a price-to-earnings ratio of -2.23 and a beta of 1.10.

Institutional Investors Weigh In On Biodesix

Several hedge funds have recently bought and sold shares of the company. Balyasny Asset Management L.P. acquired a new stake in Biodesix in the 4th quarter valued at about $29,000. Barclays PLC lifted its stake in Biodesix by 1,140.5% in the 3rd quarter. Barclays PLC now owns 23,036 shares of the company’s stock valued at $41,000 after purchasing an additional 21,179 shares during the last quarter. HighTower Advisors LLC lifted its stake in Biodesix by 17.1% in the 4th quarter. HighTower Advisors LLC now owns 153,934 shares of the company’s stock valued at $236,000 after purchasing an additional 22,500 shares during the last quarter. Geode Capital Management LLC lifted its stake in Biodesix by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 827,199 shares of the company’s stock valued at $1,266,000 after purchasing an additional 22,623 shares during the last quarter. Finally, Millennium Management LLC lifted its position in Biodesix by 20.2% during the fourth quarter. Millennium Management LLC now owns 198,671 shares of the company’s stock worth $304,000 after acquiring an additional 33,329 shares during the last quarter. 20.96% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Biodesix

In related news, CEO Scott Hutton sold 83,660 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total value of $76,967.20. Following the completion of the sale, the chief executive officer now directly owns 701,947 shares in the company, valued at approximately $645,791.24. This trade represents a 10.65 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 128,702 shares of company stock worth $118,406 in the last three months. Insiders own 69.20% of the company’s stock.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.